Leptomeningeal metastasis (LM) is a feared complication of cancer that carries an ominous prognosis. Early diagnosis coupled with vigorous treatment can improve neurological symptoms and prolong survival. [1] [2] [3] 
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sensitivity, often requiring multiple lumbar punctures to establish a diagnosis of LM. 1, 4, 5 Hence, improved diagnostic tools that can accurately detect LM at an early stage are sorely needed.
Rare cell capture technology (RCCT) (Janssen Diagnostics) is an FDA-approved method for detecting and enumerating circulating tumor cells (CTC) in the blood of patients with epithelial tumors. It exploits an immunomagnetic enrichment platform and ferroparticles covered with anti-epithelial cell adhesion molecule (EpCAM) antibody to capture EpCAM-expressing CTC. 6 This method has been used to detect CTC in the blood of patients with metastatic carcinoma, and studies have shown correlations of CTC with tumor burden, treatment response, and prognosis. [7] [8] [9] [10] Previous studies demonstrated that RCCT can be used to detect CTC in the CSF of patients with established and newly diagnosed LM. [11] [12] [13] In one study, CSF-CTC was enumerated in all 15 patients with LM; however, in one patient without definite LM, CSF-CTC was also detected, albeit at a low concentration of 0.27 CTC/mL. 11 In order to further investigate the diagnostic accuracy of CSF-CTC in the diagnosis of LM and establish optimal cutoff values, we conducted a distinct, larger study in patients with epithelial tumors with symptoms suspicious for LM.
Methods
In this institutional review board-approved prospective study, we enrolled patients with epithelial tumors who presented with neurological symptoms suspicious for LM or had MRI findings suspicious for LM and were referred for clinical CSF examination from April 2013 to December 2015. All patients underwent MRI of the brain and/or spine and CSF cytology. All CSF was collected via a lumbar puncture. Standard CSF evaluation was performed, including CSF protein, glucose, white and red cell analysis, gram stain, bacterial and fungal cultures, and cytopathology analysis. In addition, 3 mL CSF from the same lumbar puncture was collected in a CellSave preservative tube and submitted for CSF-CTC analysis. We recorded patients' demographics, cancer history and outcome, and presence of concurrent brain metastases.
For this study, a composite definition of LM was based on positive CSF cytology ( Fig. 1A and B) or unequivocal MRI findings (Fig. 1C and D) performed within a month of the CSF analysis. The one-month window was defined arbitrarily to ensure that the diagnosis of LM was new and relevant to the initial CSF-CTC result. Follow-up investigations for patients who had initial negative tests for LM were performed at the discretion of the patients' treating oncologists. Unequivocal MRI findings were defined as leptomeningeal enhancement associated with subarachnoid nodules, basal cistern enhancement, or nerve root enhancement/clumping ( Fig. 1C and D) . Suspicious but equivocal MRI findings-such as multiple superficial parenchymal brain metastases at or near the sulci, intraor periventricular masses, epidural metastases associated with dural enhancement, or new hydrocephalus-were not considered diagnostic of LM.
The methodology for detection of CSF-CTC was described previously. 11 Briefly, the CellSearch CTC Kit (Janssen Diagnostics) consists of EpCAM-bound antibody ferroparticles, fluorescent reagents (anti-cytokeratin phycoerythrin [CK-PE], 4ʹ,6-diamidino-2-phenylindole [DAPI], and anticluster of differentiation [CD]45-allophycocyanin that stain for intracellular protein CK, cell nucleus, and leukocytes, respectively), CellTracks AutoPrep System, MagNest cell presentation device, and CellTracks Analyzer II. For each 3 mL of CSF sample, EpCAM-expressing cells were captured immunomagnetically before reagents were added. The CellTracks AutoPrep System dispensed 3.5 mL of reagent/sample mixture into a cartridge that was inserted into a MagNest device where magnetically labeled cells were pulled to the surface of the cartridge by a strong magnetic field. The CellTracks Analyzer II scanned the cartridge surface, acquired images, and displayed all events with both CK-PE and DAPI staining. Two experienced technicians reviewed the events independently and selected those that fulfilled criteria for CTC: EpCAM+, CK+, DAPI+, and CD45− (Fig. 1E ). Results were reported as number of CTC/mL of CSF. Based on these definitions, we performed receiver operating characteristic (ROC) analysis to determine an optimal threshold value for CSF-CTC to diagnose LM.
Results
We enrolled 95 patients with epithelial tumors. Patient characteristics are summarized in Table 1 . The median age was 58 years (range, 29-82 y); 70% were women. Breast and lung carcinoma were the most common primary tumors. Ninety-two patients presented with neurological symptoms suspicious for LM; the most common neurological symptom was headache, followed by gait instability and sensory abnormalities. The remaining 3 patients underwent CSF evaluation because they had MRI findings suspicious for LM ( Table 2) .
Importance of the study
Leptomeningeal metastasis is a devastating complication of cancer, and effective treatment depends on early and accurate diagnosis. However, current diagnostic tools comprising CSF cytology and MRI lack sensitivity. Repeated CSF and MRI examinations are often required and even then can yield false negative results. This prospective study of CSF-CTC was conducted in 95 patients with epithelial tumors and clinical suspicion of LM. We showed that 1 CSF-CTC/mL provides the optimal threshold to diagnose LM, yielding higher sensitivity of 93% and specificity of 95%. The addition of CSF-CTC evaluation to CSF cytology and MRI may enhance early diagnosis of LM and should be considered as part of routine LM workup.
LM was diagnosed in 30 (32%) patients at initial evaluation: 12 had positive CSF cytology, 2 had MRI findings positive for LM, and 16 had positive results from both CSF cytology and MRI. The remaining 65 patients had negative CSF cytology and negative or equivocal MRI and were therefore deemed to be negative for LM at the time of initial evaluation. At the initial lumbar puncture, CSF-CTC was detected in 43 (45%) patients with a median of 19.3 CSF-CTC/mL (range, 0.33-66.7); 29 of these patients fulfilled criteria for LM based on CSF cytology or MRI. Fourteen did not meet criteria for LM, 9 of whom had follow-up evaluation: 1 with CSF cytology and MRI and 8 with MRIs alone. None of these 9 patients developed definite LM. Three patients remained alive without any neurological signs more than a year from evaluation for LM, and 2 died from systemic cancer progression within 3 months from initial evaluation for LM (Supplementary Table) .
Using ROC analysis, a cutoff of ≥1 CSF-CTC/mL provided the best threshold to diagnose LM, achieving a sensitivity of 93% (95% CI, 84%-100%), specificity of 95% (95% CI, 90%-100%), positive predictive value (PPV) 90% (95% CI, 79%-100%), and negative predictive value (NPV) 97% (95% CI, 93%-100%) ( Fig. 2A and B) .
Applying this threshold, there were 3 patients who had one or more CSF-CTC/mL but did not meet study criteria for LM by standard diagnostic tests. All 3 patients had brain metastases at the sulci or next to the ventricles from underlying breast, lung, or bladder carcinoma (Fig. 3 ). For these 3 patients, follow-up MRIs performed between 27 and 78 days from the initial CSF evaluation remained negative for LM; none had repeat CSF cytology or autopsy. Conversely, 2 patients who were diagnosed with LM by our study criteria had <1 CSF-CTC/mL (Fig. 4) . One patient had negative initial CSF cytology and was diagnosed with LM by MRI alone; the patient did not have follow-up CSF examination. The other diagnosis of LM was made in a patient by CSF cytology only.
In the 65 patients who had initial negative results for LM, 45 had follow-up tests with both CSF cytology and MRIs (n = 14), CSF cytology alone (n = 2), or MRIs alone (n = 29). Of these patients, 3 developed LM confirmed by CSF cytology at 2 months (n = 2) and 8 months (n = 1) after the initial CSF evaluation, but none of these 3 had detectable CSF-CTC at initial evaluation. Follow-up investigations remained negative in the remaining 42 patients.
Discussion
In this study, we evaluated CSF samples from 95 patients with epithelial tumors who had clinical symptoms suspicious for LM. ROC analysis showed that a threshold value of ≥1 CSF-CTC/mL provides high diagnostic sensitivity 
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(93%) and specificity (95%), PPV 90% and NPV 97%, confirming CSF-CTC as a robust tool in diagnosing LM.
Over the years, several studies using various definitions for LM have evaluated the diagnostic accuracy of CSF cytology and MRI. [14] [15] [16] Collectively, these studies have shown that MRI performed better than CSF cytology, with sensitivity ranging from 76% to 100% compared with 46% to 75% for CSF cytology. CSF cytology is highly examiner dependent, relying on the experience of the pathologist and availability of immunostaining to identify specific cancer cell types. MRI achieved a higher sensitivity compared with CSF cytology in those studies but has limitations of interreader variability and nonspecific findings that are often indistinguishable from other CNS etiologies, such as infection and inflammatory changes. The overall suboptimal sensitivity of CSF cytology and specificity of MRI have prompted studies of other CSF biomarkers. However, while these studies showed that CSF biochemical markers, including cytokeratins, tumor markers, vascular endothelial growth factor, and neuron-specific enolase were often suggestive, they were rarely diagnostic of LM. [17] [18] [19] [20] [21] Since the pilot study, 11 other studies have sought to investigate tools that exploit the expression of the transmembrane glycoprotein EpCAM on carcinomas, thereby providing more direct measurements of tumor cells and eliminating the ambiguity associated with biochemical markers and MRI. [22] [23] [24] [25] The majority of studies included only patients with either breast or lung cancers or evaluated the utility of different EpCAM-based methods on the CSF. 13, [22] [23] [24] A recent study of an innovative approach utilizing flow cytometry immunophenotyping to identify EpCAM+ cells in the CSF demonstrated a higher sensitivity (80% vs 50%) but lower specificity (84% vs 100%) for LM diagnosis compared with CSF cytology. 25 Another study of EpCAM-based flow cytometry showed 100% sensitivity and 100% specificity in relation to CSF cytology 26 ; however, the study was limited by a sample size of only 13 patients with established and newly diagnosed LM.
In our study of the largest sample size of patients undergoing evaluation for clinical suspicious LM, CSF-CTC capture by EpCAM-based RCCT had high sensitivity and specificity, which may be attributed to the RCCT method of immunomagnetic enrichment and its ability to exclude EpCAM+ leukocytes. Only 3 patients negative for LM by our study criteria had ≥1 CSF-CTC/mL. All 3 patients had large brain parenchymal metastases that were close to the CSF compartments at the ventricles or sulci, which we postulate had resulted in shedding of tumor cells into the CSF that allowed identification of CSF-CTC in the absence of established LM. Conversely, 2 patients diagnosed with LM by our study criteria had <1 CSF-CTC/mL (0 CTC/mL and 0.66 CTC/ mL). We postulate that the LM from these 2 patients, though not necessarily the primary tumors, had low expressing EpCAM below the threshold for detection. Unfortunately, none of the 4 patients with initial negative CSF cytology had follow-up CSF cytology or postmortem examinations that would have been helpful in clarifying their LM status.
The RCCT CellSearch platform is currently FDA approved for the isolation and enumeration of CTC from blood samples in patients with metastatic breast, *Some patients had more than one clinical symptom. prostate, and colorectal carcinomas. Studies examining peripheral blood CTC have demonstrated its use as both a prognostic factor for survival and a biomarker of disease status. In patients with metastatic breast carcinoma, CTC levels equal to or greater than 5 CTC per 7.5 mL of whole blood were correlated with shorter median progressionfree survival and median overall survival compared with patients with CTC levels lower than 5 per 7.5 mL of whole blood 7 ; CTC levels were also correlated with radiographic progression of disease, demonstrating its potential use as a biomarker of treatment response. 8 Similarly, baseline and changes in blood CTC numbers during treatment were correlated significantly with survival in men with progressive metastatic castration-resistant prostate cancer, 10 while high blood CTC was significantly associated with high tumor burden 27 and poor prognosis 28, 29 in patients with metastatic colorectal cancer. Future CSF-CTC studies should examine the role of CSF-CTC in prognostication and prediction of treatment response in patients with LM and include repeat CSF cytology and neuroimaging; if validated in other studies, CSF-CTC could potentially be incorporated into response criteria for LM. 30 3 MRIs of 3 patients with ≥1 CSF-CTC/mL but negative for LM by study criteria. Axial contrast T1-weighted images of patients (A1-4) and (B1-2) and (C) demonstrating brain parenchymal metastases in close proximity to CSF spaces at the sulci (white arrows) or ventricles (white arrowheads). The 3 patients with breast, bladder, and lung carcinomas had 1, 10, and 64 CSF-CTC/mL, respectively.
Our study has a number of limitations. EpCAM is an epithelial marker, and our results are only applicable to epithelial tumors, which nevertheless account for the vast majority of solid tumor patients with LM; marked loss of EpCAM expression in end-stage disease may potentially alter the performance of CSF-CTC determination. A low level contamination of epithelial cells from skin at the time of the lumbar puncture could theoretically contaminate the samples and lead to false positive results. Nonetheless, cytology review and the use of a threshold of ≥1 CTC/mL minimized this possibility. Second, LM diagnostic studies are inherently limited due to the lack of a reliable gold standard. We utilized the best methodologies currently used in clinical practice to diagnose LM, but they are associated with limited sensitivity and specificity. In addition, follow-up evaluations were based on clinical necessity and left at the discretion of treating physicians; they were not performed in a standardized manner and reflected the impracticality of mandating repeat lumbar punctures and MRIs for research purposes only, especially in the setting of endstage cancer. This diminished our ability to ascertain whether a positive CSF-CTC in the absence of cytology or unequivocal MRI findings carried any diagnostic or prognostic significance, although enhanced clinical surveillance and repeat CSF analysis are likely warranted when any CSF CTC is found. Third, we only had a significant number of patients with breast or lung primaries; hence, we were unable to determine whether the utility of CSF-CTC varies among different epithelial primaries. Finally, CSF cytology in our study was more frequently positive in comparison to other studies, potentially reflecting the use of highly experienced cytologists with access to complementary immunohistochemistry tools to identify cancer cells in the CSF. It is possible that the information provided by the CSF-CTC will be even more useful at less experienced centers and facilities.
In summary, CSF-CTC capture and enumeration by RCCT is a novel, highly sensitive method to diagnose LM and constitutes a valuable tool to improve diagnostic performance of existing techniques. We have determined that 1 CSF CTC/mL or 3 or more CTC per 3 mL of the CSF is pathognomic and should be considered in all clinical evaluations. Collected in dedicated vials, the samples can be stored up to 3 days at room temperature, allowing for shipment to dedicated centers for analysis. Based on the findings of this study, the New York State Clinical Laboratory Improvement Amendment certification was granted for the use of the RCCT platform in enumerating CTC in CSF, and this assay is now routinely offered for CSF analysis at our institution.
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